This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?
by Ahan Chakraborty
NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.
biotechnology biotechs medical pharmaceuticals
Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?
by Kanishka Das
Merck leans on Keytruda's expanding cancer indications and new SC formulation to sustain growth momentum into 2026 after soft sales in Q3.
pharmaceuticals
Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B
by Kinjel Shah
Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.
pharmaceuticals
Bristol Myers Gains 7.2% in a Month: Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.
biotechnology biotechs medical pharmaceuticals
Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?
by Aparajita Dutta
With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?
etfs pharmaceuticals
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug
by Zacks Equity Research
Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.
biotechnology biotechs earnings medical pharmaceuticals
Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call
by Kinjel Shah
Pfizer faces a fierce bidding war with Novo Nordisk over Metsera while securing a landmark U.S. drug pricing deal.
pharmaceuticals
LLY's GLP-1 Duo Boosts Sales Amid Rising Demand for Obesity Drugs
by Kinjel Shah
Lilly's Mounjaro and Zepbound continue to power growth as new launches boost momentum amid rising obesity competition.
pharmaceuticals
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus
by Zacks Equity Research
Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.
biotechnology biotechs earnings medical pharmaceuticals
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.
biotechnology biotechs earnings medical pharmaceuticals